Loading...

ADC Therapeutics SA (NYSE:ADCT)

7.76 USD -0.26 USD ( -3.24% )
Watchlist Manager
ADC Therapeutics SA
NYSE:ADCT
Watchlist

EV/EBITDA
Enterprise Value to EBITDA

The Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
=
Enterprise Value
/
EBITDA
Current EV/EBITDA
ADCT
-2
Median EV/EBITDA
ADCT
-5.2
Industry EV/EBITDA
Biotechnology
2.6

EV/EBITDA History

Statistics
Enterprise Value to EBITDA

1 Year 3 Years 5 Years
Average -5.1 435.2 264
Median -5.2 -5.2 N/A
Min -7.8 N/A N/A
Max -1.6 1 823 1 823

History Chart
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-2
2-Years Forward
EV/EBITDA
-1.8
3-Years Forward
EV/EBITDA
-4.1

EV/EBITDA Across Competitors

ADCT Competitors
ADC Therapeutics SA Competitors

Country Company Market Cap EV/EBITDA
CH
ADC Therapeutics SA
NYSE:ADCT
596M USD N/A
US
Abbvie Inc
NYSE:ABBV
268B USD 11.4
US
Amgen Inc
NASDAQ:AMGN
130B USD 14.1
AU
CSL Ltd
ASX:CSL
131B AUD 25
US
Gilead Sciences Inc
NASDAQ:GILD
78.1B USD 8.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
70.6B USD 21.5

Relative Valuation Report

View full relative valuation report for ADC Therapeutics SA, which takes into account all ADCT`s valuation multiples.

See Also

Similar Stocks